# Absorption, Metabolism, Excretion and Absolute Bioavailability

> **NCT03250039** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-04965842
- **DRUG:** Absolute Bioavailability

## Key facts

- **NCT ID:** NCT03250039
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-10
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-09-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250039, "Absorption, Metabolism, Excretion and Absolute Bioavailability". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03250039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*